| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP of Finance | VP of Finance
1 company
Angela Walsh is SVP of Finance at DWTX. Angela Walsh's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3K at current prices.
Net of sales, the DWTX filings show accumulation of 3,000 shares.
Angela Walsh has 11 Form 4 filings on record from December 2020 to March 2026, all as Chief Financial Officer at Dogwood Therapeutics (DWTX), 2020–2026.
The 11 reported transactions were 9 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $16K and no sales.
The largest open-market purchase was 2,000 shares of DWTX at an average $4.58 on May 23, 2022, about $9K. Twelve months later DWTX was down 72%.